Editor’s Note: The continued resolution discussed here expired March 4, 2025. See all of our advocacy news and alerts and funding and grants for more.
The continued resolution is set to expire March 14, 2025, and the extension currently up for a vote in the Senate is raising significant concerns for research funding within the Congressionally Directed Medical Research Program (CDMRP). Fragile X has been an authorized topic area eligible for funding under the Peer-Reviewed Medical Research Program (PRMRP) within the CDMRP since 2010. Over the years, this has led to over $21 million in grants aimed at advancing critical research in Fragile X-associated conditions, including Fragile X syndrome.
However, as the expiration of the current continued resolution looms, a concerning update has surfaced: the CDMRP could face a substantial 57% reduction in funding. While specifics about how this will impact the PRMRP program remain unclear, the potential for significant cuts in research funding is a serious concern for the Fragile X community and its advocates.
We are actively monitoring this situation and remain engaged as members of the Defense Health Research Consortium (DHRC), which has assured us that our voices are being heard in ongoing discussions. While the passage of the current continued resolution is concerning, there is hope that amendments can be made to adjust or mitigate the impact of such a steep funding reduction.
We understand how unsettling this uncertainty is for our community. Please know that we are working closely with our partners, advocating for the continuation of vital research funding. We remain committed to providing you with accurate information and will continue to collaborate with the DHRC to ensure our voices are heard and that our research priorities are protected.
